Clinical Trials Logo

Locally Advanced Sarcoma clinical trials

View clinical trials related to Locally Advanced Sarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04873375 Recruiting - Metastasis Clinical Trials

Cemiplimab for Secondary Angiosarcomas

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

Secondary angiosarcomas are aggressive mesenchymal tumors with a poor prognosis and limited therapeutic options. Recent studies conducted in patients with cutaneous squamous-cell carcinoma provide evidence that cemiplimab has the potential to be an effective treatment also for patients with secondary angiosarcomas. The purpose of this study is to evaluate the overall response rate after 24 weeks of cemiplimab treatment in patients with locally advanced or metastatic secondary angiosarcomas. The investigators hypothesis is that cemiplimab could be an effective treatment for patients diagnosed with locally advanced and metastatic secondary angiosarcomas.

NCT ID: NCT04771520 Recruiting - Metastatic Melanoma Clinical Trials

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Avapritinib may help to control the growth of malignant solid tumors.